
Acute type B aortic dissection (TBAD) remains a high-stakes emergency. The New England Journal of Medicine review by Mussa and Kougias synthesizes contemporary evidence and guidelines into a pragmatic pathway. Key points include: initial anti-impulse therapy with IV beta-blockers targeting SBP 100–120 mmHg and HR 60–80 bpm; TEVAR as the preferred modality for complicated TBAD (rupture or end-organ malperfusion); and structured, lifelong surveillance after discharge (imaging at 1, 6, and 12 months, then annually).
Classification anchors decision-making: Stanford type B dissections originate distal to the left subclavian artery (SVS–STS zones ≥2), with most uncomplicated TBADs initially managed medically and 60% presenting without rupture/malperfusion.
When complications arise (rupture or malperfusion syndromes—often dynamic branch obstruction), urgent endovascular repair to cover the proximal entry tear is recommended; adjuncts (carotid–subclavian bypass or branched endografts) may preserve subclavian flow. Open repair is reserved for unfavorable anatomy or persistent malperfusion post-TEVAR.
For “uncomplicated but high-risk” TBAD (e.g., total aortic diameter >4 cm, false lumen >22 mm, entry tear >1 cm, refractory pain/hypertension, bloody pleural effusion), early TEVAR is considered but remains based on limited data; ongoing randomized trials (IMPROVE-AD, SUNDAY, EARNEST) aim to clarify indications and timing.
Randomized evidence (INSTEAD/INSTEAD-XL; ADSORB) suggests TEVAR promotes aortic remodeling and may reduce late aorta-specific mortality and progression versus medical therapy alone, but with no early survival advantage—reinforcing careful selection and avoidance of very early (<48 h) intervention to reduce retrograde type A risk.
Finally, special populations warrant nuance: genetically triggered aortopathies generally favor medical therapy for uncomplicated TBAD and open repair when complicated (TEVAR mainly as a bridge); pregnancy calls for labetalol-based medical control when uncomplicated and standard emergency intervention when complicated.
#aorticdissection #TEVAR #vascularsurgery #cardiology #hypertension
Editorial note: This content was developed with the support of artificial intelligence technologies to optimize the writing and structuring of the information. All material was carefully reviewed, validated, and supplemented by human experts prior to publication, ensuring scientific accuracy and adherence to good editorial practices.
Sources
- Mussa FF, Kougias P. Management of Acute Type B Aortic Dissection. N Engl J Med. 2025;393(9):895-905. doi:10.1056/NEJMra2405257.
Highlights
Medical Affairs
Trastuzumab deruxtecan (T-DXd) Provides Significant Clinical Benefit Over Trastuzumab emtansine (T-DM1), Marking a Potential Shift in the Therapeutic Standard for HER2+ Breast Cancer

TribeMD
SnackableHealth™ | From Intervention to Prevention: How Secondary Prevention Clinics Are Redefining Post-ACS Care

Medical Affairs
META-AF: Metformin as an Adjunctive Therapy to Catheter Ablation of Atrial Fibrillation

Medical Affairs
Trastuzumab deruxtecan (T-DXd) Provides Significant Clinical Benefit Over Trastuzumab emtansine (T-DM1), Marking a Potential Shift in the Therapeutic Standard for HER2+ Breast Cancer

TribeMD
SnackableHealth™ | From Intervention to Prevention: How Secondary Prevention Clinics Are Redefining Post-ACS Care

Medical Affairs
META-AF: Metformin as an Adjunctive Therapy to Catheter Ablation of Atrial Fibrillation


